Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
NCT02795676
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
78
Enrollment
INDUSTRY
Sponsor class
Conditions
Fabry Disease
Interventions
BIOLOGICAL:
PRX-102 (pegunigalsidase alfa)
BIOLOGICAL:
agalsidase beta
Sponsor
Protalix
Collaborators
[object Object]